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Purpose: The purpose of this study was the intraindividual comparison of a
1.0 M and two 0.5 M gadolinium-based contrast agents (GBCA) using equi-
molar dosing in dynamic and static magnetic resonance angiography (MRA)
of the supra-aortic vessels.
Materials and Methods: In this institutional review boardYapproved study, a
total of 20 healthy volunteers (mean T SD age, 29 T 6 years) underwent 3
consecutive supra-aortic MRA examinations on a 3.0 T magnetic resonance
system. The order of GBCA (Gadobutrol, Gadobenate dimeglumine, and
Gadoterate meglumine) was randomized with a minimum interval of 48 hours
between the examinations. Before each examination and 45 minutes after each
examination, circulatory parameters were recorded. Total GBCA dose per
MRA examination was 0.1 mmol/kg with a 0.03 mmol/kg and 0.07 mmol/kg
split for dynamic and static MRA, respectively, injected at a rate of 2 mL/s.
Two blinded readers qualitatively assessed static MRA data sets independently
using pairwise rankings (superior, inferior, and equal). In addition, quantitative
analysis was performed with signal-to-noise ratio (SNR) and contrast-to-noise
ratio (CNR) evaluation as well as vessel sharpness analysis of static MRA
using an in-houseYdeveloped semiautomated tool. Dynamic MRA was eval-
uated for maximal SNR. Statistical analysis was performed using the Cohen J,
the Wilcoxon rank sum tests, and mixed effects models.
Results: No significant differences of hemodynamic parameters were ob-
served. In static MRA, Gadobutrol was rated superior to Gadoterate meglu-
mine (P G 0.05) and equal to Gadobenate dimeglumine (P = 0.06) with good
to excellent reader agreement (J, 0.66Y0.83). In static MRA, SNR was sig-
nificantly higher using 1.0 M Gadobutrol as compared with either 0.5 M agent
(P G 0.05 and P G 0.05) and CNR was significantly higher as compared with
Gadoterate meglumine (P G 0.05), whereas CNR values of Gadobutrol data
sets were not significantly different as compared with Gadobenate dimeglu-
mine (P = 0.13). Differences in CNR between Gadobenate dimeglumine and
Gadoterate meglumine were not significant (P = 0.78). Differences in vessel
sharpness between the different GBCAs were also not significant (P 9 0.05).
Maximal SNR in dynamic MRA using Gadobutrol was significantly higher
than both comparators at the level of the proximal and distal internal carotid ar-
tery (P G 0.05 and P G 0.05; P G 0.05 and P G 0.05).
Conclusions: At equimolar doses, 1.0 M Gadobutrol demonstrates higher
SNR/CNR than do Gadobenate dimeglumine and Gadoterate meglumine, with
superior image quality as compared with Gadoterate meglumine for dynamic and
static carotid MRA. Despite the shortened bolus with Gadobutrol, no blurring of
vessel edges was observed.
Key Words: magnetic resonance angiography, contrast media, carotid
arteries, vessel blurring, image quality, Gadobutrol, Gadobenate
dimeglumine, Gadoterate meglumine
(Invest Radiol 2013;48: 121Y128)
A cute arterial events are among the most frequent causes of pre-mature death in the developed world, and cerebrovascular events
have replaced cardiac events as the leading cause of death. Therefore,
interest in imaging of the supra-aortic vessels has significantly
increased.1Y3 In most vascular territories, digital subtraction angiog-
raphy still remains the standard of reference.4,5 However, the known
drawbacks of digital subtraction angiography have spurred the de-
velopment of noninvasive techniques.6,7 Because of recent develop-
ments, magnetic resonance angiography (MRA) is now routinely used,
along with computer tomographic angiography or ultrasound.7Y10 The
image quality of MRA is enhanced with the use of dedicated gado-
linium-based contrast agents (GBCA),11Y14 which improve signal-to-
noise ratio (SNR) and contrast-to-noise ratio (CNR).14Y16
However, because of the description of a potential link be-
tween the applications of GBCAs and the development of nephro-
genic systemic fibrosis (NSF),17,18 efforts are made to reduce the
amount of GBCA administered for comprehensive diagnostic imag-
ing of the arterial vasculature.8,19 Although earlier studies proposed
higher doses of standard GBCA,20Y22 currently, MRA examinations
are typically performed at single doses (0.1 mmol/kg). Furthermore,
the current state-of-the-art MRA of the cervical arteries comprises
high-resolution static and dynamic imaging. Previously published
studies have shown that, using standard GBCA, excellent image
quality is possible using a single dose, and good image quality is
possible even with lower than single doses.9,23Y25 However, reducing
the amount of injected contrast agent results in a shortening of the bolus
because a certain injection rate is needed to keep the bolus tight.
Sampling of the peripheral parts of k-space without the presence of
contrast agent bolus theoretically leads to blurring of the vessel edges.26
We hypothesized that, in supra-aortic MRA, 1.0 M Gadobutrol
is noninferior to 0.5 M Gadobenate dimeglumine and superior to
Gadoterate meglumine when applied at single equimolar dose. The
purpose of this study therefore was to intraindividually compare all 3
GBCAs in dynamic and static supra-aortic MRAwith application of
identical imaging and dosage parameters in respect to qualitative
image quality and quantitative signal parameters.
MATERIALS AND METHODS
Study Population
This single-center, blinded, prospective, intraindividual com-
parison study was approved by the institutional review board, and
written informed consent was obtained from all study volunteers.
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Twenty-two healthy men (mean T SD age, 28.7 T 5.9 years;
range, 21Y41 years) without history of vascular or renal disease,
without contraindication against any of the investigational GBCA, or
without general magnetic resonance (MR) contraindications were
included between June 2011 and August 2011.
Before inclusion in the study, a blood sample was drawn from
every volunteer and the glomerular filtration rate was calculated us-
ing the Cockroft-Gault formula (eGFR) and confirmed to be greater
than 60 mL/min per 1.73 m2.
Magnetic Resonance Imaging and Study Protocol
All MRA examinations were performed on a 3.0 T 32-channel
whole-body open-bore MR system (Magnetom Verio; Siemens
Healthcare, Erlangen, Germany). For signal reception, a 12-element
head array coil in combination with a 4-element neck surface coil
was used.
For static MRA, a standard 3-dimensional fast low-angle shot
sequence with parameters optimized for 3.0 T was used. Because
image quality in terms of SNR is regarded as sufficient at 1.5 T, the
potential increase in signal at 3.0 Twas invested in increasing spatial
resolution and shortening the acquisition time. Readout was done in a
centric fashion with a time to center of 1 second. Because optimizing
sequence parameters for 1 agent would penalize both remaining
agents, the sequence settings were chosen to reflect the state-of-the-
art 3.0 T MRA parameters. Detailed sequence parameters can be
found in Table 1. For dynamic MRA, a time-resolved angiography
with interleaved stochastic trajectories sequence was used.27 This
sequence is based on a view-sharing technique and facilitates in
setting the size of the central region of k-space, which is sampled at
every time point, and the sampling density of the remaining periph-
eral part of k-space. Because, in this study, a high spatial resolution
static data set was acquired as well, dynamic MRAwas optimized for
temporal information. Hence, spatial resolution and potentially
available signal were sacrificed to increase temporal resolution. De-
tailed sequence information can be found in Table 1.
The volunteers were imaged at 3 different time points with the
3 different contrast agents administered in a randomized fashion and
a delay of 48 hours to 30 days between individual GBCA applica-
tions. Hemodynamic parameters (eg, blood pressure, heart rate) were
recorded before each scan, and an 18-Gauge venous access was placed
in the right antecubital vein. Total GBCA dose per examination was
0.1 mmol/kg body weight (BW) with a 70%Y30% split for static and
dynamic MRA, respectively. Static MRA was always performed as the
first of both examinations to exclude any effect of the previously ad-
ministered contrast agent on SNR and CNR measurements on static
MRA data sets. All GBCA injections were performed using a power
injector (Spectris Solaris; Medrad). For the evaluation of bolus arrival
time, a test bolus technique with a fixed dose of 1 mL of contrast agent
injected at a flow rate of 2 mL/s, followed by a 20 m/L saline chase
injected at the same rate, was used. Both static and dynamic MRAwere
performed with the same injection parameters.9,27 After each examina-
tion, hemodynamic parameters were reassessed and the volunteers were
monitored for the occurrence of adverse events for 60 minutes.
Contrast Agents
The following Gd-based contrast agents (GBCAs) were used
for this study: Gadobutrol (Gadovist/Gadavist; Bayer Healthcare,
Berlin, Germany), Gadobenate dimeglumine (Multihance; Bracco Di-
agnostics, Milan, Italy), and Gadoterate meglumine (Dotarem; Guerbet,
Roissy CdG Cedex, France).
Gadobutrol is a 1.0 M macrocyclic GBCA with a relaxivity
(L mmolj1 sj1) of 5.0 (4.7Y5.3) at 3.0 T. Gadobenate meglumine is a
0.5 M linear GBCA with a weak transient protein binding and a
relaxivity of 5.5 (5.2Y5.8) at 3.0 T. Gadoterate meglumine is a 0.5 M
macrocyclic GBCA and a relaxivity of 3.5 (3.3Y3.7) at 3.0 T.14
Image Quality Evaluation
Qualitative image quality of all static MRA data sets was
assessed independently by 2 radiologists with more than 10 years of
experience in MRA using pairwise comparisons. The readers were
asked to give their overall impression on whether a data set was
better, equal, or worse than the given comparator. The readers in-
cluded measures such as vessel conspicuity and vessel homogeneity
in their judgment but excluded factors that are not related to a certain
contrast agent, for example, venous enhancement. Both observers
were blinded to any information about the used contrast agent, and
after the independent evaluation, assessments of both readers were
combined, as shown in Table 2.
Quantitative analysis of both static and dynamic MRA data
sets was performed on the basis of the assessment of SNR and CNR
at the level of the proximal internal carotid artery (ICA) next to the
carotid bifurcation and at the distal ICA just proximal to the carotid T
at the level of the skull base. Because the static and dynamic MRA
acquisitions used parallel imaging techniques, SNR and CNR eval-
uations were performed by applying the difference method, as
previously described by Dietrich et al.28 Hence, 2 consecutive un-
enhanced data sets were acquired before the contrast agent applica-
tion and subtracted from each other. The SD within a region of
interest (ROI) positioned in the subtracted data set at identical posi-
tion as the signal measurement in the enhanced data set was de-
fined as image noise for that specific location. For calculation of
TABLE 1. Sequence Details of Static MRA and Dynamic MRA
Static MRA Dynamic MRA
Acquisition time, seconds 21.6 98
Temporal resolution, seconds V 1.85; interp, 0.925
Parallel imaging factor 4 3
Spatial resolution, mm3 0.8  0.8  0.8 1.4  1.4  1.4
TR (repetition time), milliseconds] 3.25 2.46
TE (echo time), milliseconds 1.26 0.92
Flip angle, degrees 21 18
Matrix 576  342 256  176
FOV, mm2 450  267 350  240
Bandwidth, Hz 620 810
Note the excellent spatial resolution of both techniques and the temporal
resolution of less than 2 seconds per frame of dynamic MRA interpolated to
0.925 seconds per frame.
TABLE 2. Calculation of Combined Results From Blinded Image
Quality Reading
Reader 1 Reader 2 Combined Result
CA A is superior CA A is superior CA A is superior
CA A is superior both equal CA A is superior
CA A is superior CA B is superior both equal
both equal CA A is superior CA A is superior
both equal both equal both equal
both equal CA B is superior CA B is superior
CA B is superior CA A is superior both equal
CA B is superior both equal CA B is superior
CA B is superior CA B is superior CA B is superior
CA A indicates contrast agent A; CA B, contrast agent B.
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contrast between the vessel signal and the surrounding tissues, an
ROI was positioned within the masseter muscle.
In addition to SNR and CNR evaluation, a semiautomated
quantitative evaluation of the vessel edge sharpness was performed
using an in-houseYdeveloped MATLAB-based tool (MathWorks,
Natick, MA). After a user-based identification of the center of the
vessel of interest on an axial reformatted slice, the tool automatically
generated 6 equally spaced radial spokes in 30-degree intervals. Each
of the 6 spokes provided a line profile and 2 vessel edges, for a total
of 12 vessel edges. Vessel edge sharpness (mm) was defined as the
distance between the 20% and 80% of the maximum signal intensity
on each side of the line profile (Fig. 1). Vessel edge sharpness was
averaged over all 12 vessel edges.
Statistical Analysis
For the assessment of contrast agent superiority via qualitative
pairwise preference comparisons, a Wilcoxon signed rank test and
the Cohen J for the assessment of interreader agreement were
used. For the assessment of quantitative parameters such as SNR,
CNR, and vessel edge sharpness, linear mixed effects models,
Kruskal-Wallis tests, and the Wilcoxon rank sum test were used. P G
0.05 (2-sided) was considered as statistically significant. Computa-
tions were done using measurements of all the volunteers; given
values are mean values. Given SDs are mean values of measured
SDs. All computations were done in R for Windows, version 2.12.1
(R Development Core Team, 2009).
RESULTS
All contrast agents were administered at 0.1 mmol/kg with a
70%Y30% split for static and dynamic MRA. This resulted in a mean
T SD volume of 11.2 (1.1) mL for the 0.5 M agents, 5.6 (0.6) mL for
gadobutrol for static MRA, and 4.8 (0.5) mL and 2.4 (0.2) mL for the
0.5 M and 1.0 M agents for dynamic MRA, respectively.
Qualitative Analysis
In none of the volunteers circulatory parameters in terms of blood
pressure and heart rate differed significantly from each other between the
three different exams. No significant differences were observed between
the pre-examination and postexamination measurements. In addition,
because the investigated cohort consists of healthy, relatively young men,
no significantly different circulatory parameters occurred interindividually.
Combined results of the pairwise comparison of static MRA
data sets acquired with Gadobutrol, Gadobenate dimeglumine, and
Gadoterate meglumine showed Gadobutrol superior to Gadobenate
dimeglumine in 10 (50%) cases and to Gadoterate meglumine in 17
(85%) cases. It was rated as equal to the comparator in 7 and 2 cases
(35% and 10%) when compared with Gadobenate dimeglumine and
Gadoterate meglumine, respectively. Gadobutrol was judged as in-
ferior compared with Gadobenate dimeglumine and Gadoterate
meglumine in 3 and 1 case (15% and 5%), respectively. Gadobenate
dimeglumine was judged as superior, equal, or inferior as compared
with Gadoterate meglumine in 10, 5, and 5 cases (50%, 25%, and
25%; Fig. 2; Table 3). The Wilcoxon rank test revealed Gadobutrol to
be insignificantly different compared with Gadobenate dimeglumine
(P = 0.057) but significantly superior as compared with Gadoterate
meglumine (P G 0.005). Gadobenate dimeglumine was rated as not
significantly different from Gadoterate meglumine (P = 0.21). The
interreader agreement for this qualitative pairwise evaluation was
good to excellent with Cohen J values of 0.66 to 0.83 for the com-
parison of Gadobutrol with Gadobenate dimeglumine (k = 0.66) and
Gadoterate meglumine (k = 0.83) as well as Gadobenate dimeglu-
mine and Gadoterate meglumine (k = 0.66) (Table 4).
Quantitative Analysis
Static MRA
Gadobutrol featured significantly higher SNR at the level
of the proximal ICA as compared with Gadobenate dimeglumine
(P G 0.05) and Gadoterate meglumine (P G 0.05), with values of
FIGURE 1. Example of static MRA of the carotid arteries showing the level of the vessel sharpness evaluation and the reconstructed
axial slice including vessel profile lines. The graph shows an exemplary vessel signal profile with d1 and d1’ representing 20%
of the maximal signal, d2 and d2’ representing 80% of the maximal signal and full width half max level.
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87.4 T 4.2, 47.8 T 4.0, and 44.9 T 3.5 (55% and 51% of SNR
achieved with gadobutrol), respectively. In the distal ICA at the level
of the skull base, SNR was not significantly different between all
agents with values of 81.7 T 5.6, 58.4 T 7.1 (71%), and 52.0 T 5.8
(64%) for Gadobutrol, Gadobenate dimeglumine, and Gadoterate
meglumine, respectively. Contrast-to-noise ratio in MRA data sets
acquired with Gadobutrol again was superior as compared with
Gadobenate dimeglumine (P = 0.13) and significantly better than
Gadoterate meglumine (P = 0.03), with values of 71.1 T 3.8, 36.9 T 3.9
(52%), and 30.5 T 3.5 (43%), respectively (Fig. 3). Calculation of
vessel sharpness revealed no significant different results for all 3
agents with values of 1.17 T 0.24 mm, 1.05 T 0.18 mm, and 1.11 T
0.27 mm for Gadobutrol, Gadobenate dimeglumine, and Gadoterate
meglumine, respectively.
Dynamic MRA
The absence of significant interindividual and intraindividual
differences in terms of hemodynamic parameters is reflected by the
finding that the mean maximal SNR is reached within a range of 3
time frames (18.5Y21 sec. p.i. in the proximal ICA and 20Y22 sec.
p.i. at the level of the skull base) in all examinations. Dynamic MRA
such as static MRA showed higher SNR of Gadobutrol as compared
with both comparators at the 2 investigated levels in the proximal
ICA and at the level of the skull base (all P G 0.05). At the level of the
proximal ICA, Gadobutrol, Gadobenate dimeglumine, and Gadote-
rate meglumine reached a maximal SNR of 76.73, 59.41 (77%), and
43.99 (57%), respectively. At the level of the skull base, agents
reached a maximal SNR of 117.77, 83.77 (71%), and 71.22 (60%),
respectively (Fig. 4).
TABLE 3. Results of Combined Qualitative Image Quality
Assessment
Frequency %
Gadobutrol 9 Gd-BOPTA 10 50
Gadobutrol G Gd-BOPTA 3 15
Gadobutrol = Gd-BOPTA 7 35
Gadobutrol 9 Gd-DOTA 17 85
Gadobutrol G Gd-DOTA 1 5
Gadobutrol = Gd-DOTA 2 10
Gd-BOPTA 9 Gd-DOTA 10 50
Gd-BOPTA G Gd-DOTA 5 25
Gd-BOPTA = Gd-DOTA 5 25
Gd-BOPTA indicates gadobenate dimeglumine; Gd-DOTA,
gadoterate meglumine.
FIGURE 2. Examples of the static MRA examinations acquired with Gadobutrol (A), Gadobenate dimeglumine (B), and
Gadoterate meglumine (C). Note the already visually assessable differences in signal intensity and image contrast. No significant
differences in edge blurring are visible.
FIGURE 3. Signal-to-noise ratio at both levels of interest and
CNR for gadobutrol, Gadobenate dimeglumine, and
Gadoterate meglumine.
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DISCUSSION
Recent publications have shown that MRA has evolved as a
method for accurate imaging of the head and neck vasculature at
high image quality over the last decade.7,9,29,30 However, there are
several factors influencing image quality of such examinations. High
field strength 3.0 T MR systems, besides 1.5 T MR systems, now-
adays can be regarded as the clinical standard, which is beneficial
for multiple MRI applications, particularly MRA.31Y34 Although it is
FIGURE 4. Signal-time curves for dynamic MRA acquired with the 3 different GBCA at the level of the proximal ICA (AYC) and at the
level of the skull base (EYG). D and H show signal-time curves for all GBCA in comparison at respective locations. Note that the SNR
curve of Gadobenate dimeglumine, although lower at the first-pass peak and the initial curve decline, approaches the SNR of
Gadobutrol in the very last stages of the dynamic MRA data acquisition.
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possible to do MRA with many different GBCA, the properties of
these agents differ and may affect the image quality of MRA. These
characteristics are influenced by multiple different factors such as
molecular structure and size, interaction with blood components, and
concentration, whereas all of them influence the relaxivity of an
agent.14 In this study, 3 main groups of available GBCA were com-
pared: (a) agents without interaction with blood components at
standard concentration (Gadoterate meglumine), (b) agents with in-
teraction with blood components at standard concentration (Gado-
benate dimeglumine), and (c) agents without interaction with blood
components at higher concentration (Gadobutrol). Agents featuring
interaction with blood components at a concentration higher than
0.5 M are not currently clinically available. Previous publications
have already shown that interaction with or binding to certain blood
components, in addition to higher Gd concentration, are beneficial as
compared with the standard GBCA for certain MRI applications, for
example, imaging of brain lesions.12,35Y38 However, because some
agents change their characteristics between injection, imaging, and
excretion, results from morphological imaging studies are not totally
transferable to MRA. In addition, results from MRA studies of cer-
tain anatomical areas are not transferrable to other areas without
careful interrogation because injection volume and injection rate, in
addition to contrast agent travel time, influence the concentration of
contrast agent in the ROI significantly. The differences in molar
concentration of the applied GBCAs resulted in different injection
volumes affecting contrast agent bolus characteristics. This cannot be
easily corrected for; in fact, the shorter bolus geometry may also
result in more complex effects.
Just reducing the injection rate of the 1.0 M agent by 50% or
increasing the rate by 100% for the 0.5 M agents does not adjust the
bolus geometry. Especially, increasing injection rate may lead to
drawbacks because the achieved signal is not linear to the concen-
tration but actually decreases at high concentrations. Morelli et al24
could show that doubling the injection rate does not lead to a sig-
nificant increase in SNR and diagnostic window.39 For static MRA,
0.07 mmol/kg are less than the recommended single dose; however,
this low-dose approach accounts for all of the compared contrast
agents and thus does not constitute a drawback for any of the agents
as compared with the others. Our results show that, under the given
conditions, the increased Gd concentration of Gadobutrol seems to be
of higher importance than does the interaction with blood proteins of
Gadobenate dimeglumine for carotid MRA. Recent studies showed
that increasing the injection rate and thus the concentration within the
blood does not necessarily lead to a higher signal.40 The in vitro
higher relaxivity of Gadobenate dimeglumine is not reflected in
qualitative and quantitative in vivo results. This might be caused by
the fact that data acquisition in carotid MRA happens approximately
15 to 20 seconds after contrast agent injection. Morphologic imag-
ing, where Gadobenate dimeglumine shows not significantly different
or higher SNR values as compared with Gadobutrol,12,35,41 is per-
formed approximately 3 to 5 minutes after contrast agent application.
This leads to the assumption that the maximal relaxivity of Gadobe-
nate dimeglumine is not reached directly after injection. In fact, it
was already observed with other contrast agents featuring protein
binding that the full relaxivity of these agents change over time; that
is, relaxivity is lower in the arterial first pass than in the postbolus
phase.42 This might be related to incomplete contribution of protein
binding in the highly concentrated contrast bolus, where the actual
albumin excess might not be sufficient for Gadobenate dimeglumine
to allow for reaching its maximum relaxivity.43 However, this effect
can only be assumed for the first minutes after contrast agent appli-
cation because Neira et al44 could show a decrease in blood R1
within 10 minutes after contrast agent application. The lower in vitro
relaxivity of Gadoterate meglumine is consistently reflected by qual-
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image quality reading comparing the agents side by side are perfectly
supported by the quantitative measurements. The significantly higher
SNR and CNR of MRA data sets acquired with Gadobutrol lead to a
significantly higher qualitative rating of these data sets. However, CNR
values in MRA are of lesser importance because reading these data
sets is mostly done after background subtraction. The different ratio in
between SNR values for the different agents at different locations can
be explained in several ways, for example, the nonlinearity of signal as
compared with contrast agent concentration and the variation of signal
at different flow velocities. Both are true when comparing measure-
ments at the proximal and distal ICA. Partial volume effects in smaller
vessels and the coverage with different coils can explain the differences
in SNR at the evaluated levels achieved with all GBCAs.33,45
Edge blurring, as it theoretically occurs if only the center parts of
k-space are sampled during the presence of contrast agent in the ROI,
could be expected because of the small injected volume when using
Gadobutrol. Indeed, it was neither quantitatively measurable nor reflec-
ted in an impaired qualitative image quality, and no significant differ-
ences occurred comparing the 3 evaluated agents. This leads to the
conclusion that 0.07 mmol/kg BWof a 1.0 M GBCA injected at 2.0mL/s
serves with a sufficiently long contrast agent bolus to avoid disturbing
edge blurring; that is, contrast agent is present in the vascular territory
of interest during the entire k-space sampling in an adequate amount.
Since the introduction of dynamic MRA, this technique has
undergone great improvement in spatial and temporal resolution and,
nowadays, can add valuable information to an MRA examination.
However, there is still a trade-off between dynamic information and
spatial resolution, meaning, that dynamic MRA cannot completely
replace static MRA presently. To further push the image quality of
dynamic MRA, this technique benefits from dedicated contrast
agents as well.46 Signal-to-noise ratio evaluation of dynamic MRA
data sets again showed higher values achieved with a highly con-
centrated GBCA as compared with the standard 0.5 M GBCA. The
fact that SNR values achieved with dynamic MRA differ from those
measured in static MRA and that the ratio between all agents is dif-
ferent from this measured in static MRA is sequence inherent. The
technique we used for dynamic MRA relies on view sharing where
only the center part of k-space, which encodes for the contrast in the
image, is sampled for every point in time, and the peripheral parts of
k-space are shared between different frames. In dynamic MRA, the
SNR differences between Gadobenate dimeglumine and Gadoterate
meglumine as compared with Gadobutrol are less pronounced than in
static MRA. This can be rationalized by the used sequence settings
and the injection parameters. The sequence used for dynamic MRA
facilitates in setting the size of the central region A of k-space, which
is sampled in every time frame, and the sampling density of the pe-
ripheral part B of k-space. Because we selected a size of 17% of the
entire k-space for region A, which is relatively small, some parts of
the central k-space that contribute to the contrasts in the image are
sampled as part of the periphery. Sampling density of 20% for region
B in combination with a temporal resolution of 1.86 seconds per
frame ends up in a temporal footprint for sampling the entire k-space
data for 1 time frame of approximately 9 seconds. An injection rate of
2 mL/s of 0.03 mmol/kg BW (È4.5 mL for Gadobenate dimeglumine
and Gadoterate meglumine/È2.3 mL for Gadobutrol in a 75 kg par-
ticipant) results in a bolus shorter than 1 temporal footprint. For a
very short bolus, as it is a fact when using Gadobutrol, it means that
not all central k-space sampling is done during the presence of a
contrast agent. However, the resulting signal is averaged from the
entire temporal footprint, resulting in a lower signal in the final image
than the actual reached maximum during acquisition. On the other
hand, for a bolus long enough for a footprint, it results in a higher
mean signal over the sampling time.
Findings at the later time frames of signal curves beyond the ar-
terial peak enhancement show the effect of interaction of Gadobenate
dimeglumine with blood proteins. Signal curves of Gadobutrol and
Gadoterate meglumine both flatten with time. The curve of Gadobenate
dimeglumine also flattens but much less than that of both comparators,
most likely because of the prolonged presence of Gadobenate dime-
glumine in the blood pool. At the last sampled time point (98 sec. p.i.),
the signal curves of Gadobutrol and Gadobenate dimeglumine nearly
intersect; this might explain the finding of other publications that show
no significant differences between Gadobutrol and Gadobenate dime-
glumine in peripheral MRA.
A limitation of this study is the exclusive evaluation of vol-
unteer data sets without any pathologic findings. Thus, evaluation of
the influence of different SNR on diagnostic accuracy was not pos-
sible. However, this was not an aim of the current study and will be
evaluated in the future. Three different examinations with required
intervals in between in a patient with potentially severe carotid ar-
tery disease are delaying necessary treatment and are thus ethically
unjustifiable.
CONCLUSION
This study indicates that, in static and dynamic MRA of the
carotid arteries, a contrast agent that features a higher Gd concen-
tration shows higher qualitative image quality and higher SNR and
CNR as compared with 0.5 M agents, regardless of whether they
feature protein interaction/binding or not. Because we could not
confirm the finding that contrast agents with at least temporary
binding to blood components are beneficial for morphologic imaging
for MRA applications, it seems that the high relaxivity of these
agents due to concentration differences of contrast agent molecules
and human albumin in the first-pass bolus is reached after some time
of interaction with blood components but not directly after injection.
However, these agents might be superior because of the higher
relaxivity in later phase imaging. Our results reflect findings in ca-
rotid MRA, and the evaluated characteristics might be different in
other vascular territories that are imaged with an extended delay after
injection. Using a highly concentrated GBCA enables comprehensive
static and dynamicMRA imaging of the head and neck arteries without
the need to exceed the recommended dosage of 0.1 mmol/kg BW.
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